Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

ClinicalTrials.gov ID: NCT04686305

Public ClinicalTrials.gov record NCT04686305. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)

Study identification

NCT ID: NCT04686305
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: AstraZeneca; Industry
Enrollment: 304 participants

Conditions and interventions

Conditions

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions

Carboplatin Drug
Cisplatin Drug
Durvalumab Biological
Pemetrexed Drug
Rilvegostomig Drug
T-DXd Drug
Volrustomig Drug

Drug · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 8, 2021
Primary completion: Jun 29, 2027
Completion: Jun 29, 2027
Last update posted: Apr 12, 2026

2021 – 2027

United States locations

U.S. sites: 13
U.S. states: 8
U.S. cities: 13

Facility	City	State	ZIP	Site status
Research Site	Duarte	California	91010	Withdrawn
Research Site	Newport Beach	California	92663	Withdrawn
Research Site	Orange	California	92868	Recruiting
Research Site	Santa Rosa	California	95403	Withdrawn
Research Site	Westwood	Kansas	66205	Withdrawn
Research Site	Baltimore	Maryland	21287	Recruiting
Research Site	Detroit	Michigan	48201	Withdrawn
Research Site	Buffalo	New York	14263	Withdrawn
Research Site	New York	New York	10029	Withdrawn
Research Site	The Bronx	New York	10461	Withdrawn
Research Site	Houston	Texas	77030	Recruiting
Research Site	Fairfax	Virginia	22031	Recruiting
Research Site	Tacoma	Washington	98405	Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 78 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04686305, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 12, 2026 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04686305 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →